AstraZeneca Pharma India To Launch Lokelma For Hyperkalemia Treatment In November

New renal therapy enters Indian market

AstraZeneca Pharma India Ltd has announced the upcoming launch of Lokelma, a sodium zirconium cyclosilicate powder for oral suspension, in November 2025. Lokelma is indicated for the treatment of hyperkalemia—a condition characterized by elevated potassium levels in the blood, which can be life-threatening if left untreated. The launch will initially feature the 5g formulation, with the 10g version approved but not yet scheduled for release.

The company received Import and Marketing Permission in Form CT-20 from the Drugs Controller General of India (DCGI) in March 2025. This regulatory clearance enables AstraZeneca to introduce Lokelma as part of its expanding renal care portfolio, addressing a critical unmet need in cardiovascular and metabolic disease management.

Therapeutic relevance and clinical impact

Hyperkalemia is commonly associated with chronic kidney disease, heart failure, and diabetes. Lokelma offers a rapid and sustained potassium-lowering effect, making it a valuable option for clinicians managing high-risk patients. The product has already gained traction in global markets and is expected to enhance treatment outcomes in India.

Key highlights of the announcement

- AstraZeneca Pharma India to launch Lokelma (sodium zirconium cyclosilicate) in November 2025  
- The 5g oral suspension is approved for treating hyperkalemia in adult patients  
- DCGI granted marketing authorization in March 2025 for both 5g and 10g formulations  
- Lokelma is part of AstraZeneca’s renal care expansion strategy in India  
- The launch addresses a growing need for effective potassium management therapies  

Market outlook and strategic positioning

The introduction of Lokelma aligns with AstraZeneca’s commitment to delivering innovative therapies in India’s specialty care segment. With rising prevalence of chronic kidney and cardiovascular conditions, the demand for targeted treatments like Lokelma is expected to grow. AstraZeneca’s strong regulatory track record and global experience position it well for successful market penetration.

This launch also reinforces the company’s broader strategy to strengthen its presence in India’s non-communicable disease space, offering high-quality solutions backed by clinical evidence and global standards.

Sources: Business Upturn, ScanX News, AstraZeneca India Press Release